415 related articles for article (PubMed ID: 27003434)
1. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
[TBL] [Abstract][Full Text] [Related]
2. Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy.
Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Vitti P; Marcocci C; Brunetto M; Marinò M
Thyroid; 2015 Jul; 25(7):846-50. PubMed ID: 26090805
[TBL] [Abstract][Full Text] [Related]
3. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.
Covelli D; Vannucchi G; Campi I; Currò N; D'Ambrosio R; Maggioni M; Gianelli U; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2015 May; 100(5):1731-7. PubMed ID: 25751109
[TBL] [Abstract][Full Text] [Related]
4. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
5. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
Sabini E; Sisti E; Coco B; Leo M; Ionni I; Menconi F; Profilo MA; Mazzi B; Rocchi R; Latrofa F; Vitti P; Brunetto M; Marcocci C; Marinò M
J Endocrinol Invest; 2016 Nov; 39(11):1323-1327. PubMed ID: 27465669
[TBL] [Abstract][Full Text] [Related]
6. Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study.
Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Albano E; Vitti P; Marcocci C; Brunetto M; Marinò M
Eur J Endocrinol; 2015 Mar; 172(3):269-76. PubMed ID: 25661744
[TBL] [Abstract][Full Text] [Related]
7. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.
Marcocci C; Watt T; Altea MA; Rasmussen AK; Feldt-Rasmussen U; Orgiazzi J; Bartalena L;
Eur J Endocrinol; 2012 Feb; 166(2):247-53. PubMed ID: 22058081
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
9. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy.
Gao G; Dai J; Qian Y; Ma F
Clin Exp Ophthalmol; 2014 Nov; 42(8):769-77. PubMed ID: 24617953
[TBL] [Abstract][Full Text] [Related]
12. Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review.
Zoubek ME; Pinazo-Bandera J; Ortega-Alonso A; Hernández N; Crespo J; Contreras F; Medina-Cáliz I; Sanabria-Cabrera J; Sanjuan-Jiménez R; González-Jiménez A; García-Cortés M; Lucena MI; Andrade RJ; Robles-Díaz M
United European Gastroenterol J; 2019 Jul; 7(6):825-837. PubMed ID: 31316787
[TBL] [Abstract][Full Text] [Related]
13. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
15. Methylprednisolone-induced liver injury: a diagnostic challenge.
Melamud B; Lurie Y; Goldin E; Levi I; Esayag Y
Isr Med Assoc J; 2014 Mar; 16(3):180-1. PubMed ID: 24761710
[No Abstract] [Full Text] [Related]
16. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
17. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
Bartalena L; Veronesi G; Krassas GE; Wiersinga WM; Marcocci C; Marinò M; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G; Perros P; Kahaly GJ;
J Endocrinol Invest; 2017 May; 40(5):547-553. PubMed ID: 28176220
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
19. Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy.
Wichary H; Gasińska T
Thyroid; 2012 Jan; 22(1):64-9. PubMed ID: 22029719
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
